Trulieve Cannabis (TRLV) fully repaid approximately $65 million in mortgage notes payable secured by a cultivation site in Jefferson County, Florida.
The repayment reduced outstanding debt to approximately $225 million and occurred before maturity. Trulieve said cash generation funded the repayment and that lower leverage reduces annual interest expense, improving profitability and cash flow. The company also sees itself as positioned to fund near-term growth initiatives, including expansion in Georgia and Texas, pending regulatory approvals.
Trulieve Cannabis (TRLV) will hold its third-quarter 2026 results conference call on November 5, 2026, following the release of its financial results.
The call starts at 8:30 AM Eastern Time. Chairman and CEO Kim Rivers and CFO Jan Reese will review financial and operating results. A live audio webcast and an archived replay will be available.
Trulieve (TRLV) secured exclusive, perpetual, royalty-free rights from Connected for Alien Labs and Connected cannabis products in Florida and Texas.
The master license covers cultivation, manufacturing and sales using Connected's genetics, trademarks and proprietary know-how. Trulieve has offered the brands in Florida since 2022 and plans to add product categories and form factors there. Its planned Texas introduction depends on final licensure and regulatory approvals. The agreement gives Trulieve an opportunity to negotiate rights in additional markets. The companies also plan collaborative marketing campaigns.
Trulieve Cannabis Corp. (TRLV) has been added to the S&P Total Market Index, S&P Completion Index, and related health care sector sub-indices. This follows its New York Stock Exchange listing and U.S. domestication. The company said index inclusion can raise Trulieve’s visibility in U.S. equity markets, potentially improving stock liquidity and helping attract additional institutional investors.
Trulieve Cannabis (TRLV) will open a new medical cannabis dispensary in Dunwoody, Georgia, with a grand opening on September 10.
The DeKalb County location will host a ribbon cutting at 9:30 a.m. and offer storewide discounts and giveaways. The dispensary at 4675 N. Shallowford Road, Suite 100, operates 10 a.m.–7 p.m. Sunday–Thursday and 10 a.m.–8 p.m. Friday–Saturday, featuring multiple in-house brands in formats such as capsules, flower, tinctures, topicals, troches, and vaporizers.
Trulieve Cannabis (TRLV) will participate in two investor conferences in September 2026. On September 9, 2026, Chief Corporate Affairs and Strategy Officer Christine Hersey will join investor meetings at the ATB Cormark Capital Markets 2026 Fall Institutional Investor Conference. On September 29, 2026, Founder and CEO Kim Rivers will participate in investor meetings at the 5th Annual Roth Healthcare Opportunities Conference. Event details, access links, and presentations are available on Trulieve’s investor relations events webpage.
Trulieve (NYSE: TRLV) will ring The Closing Bell® at the New York Stock Exchange at 4:00 p.m. ET on August 18, 2026, to celebrate its June 10, 2026 NYSE listing. According to the company, Trulieve is the first U.S. cannabis company listed on the NYSE.
Founder and CEO Kim Rivers will lead the ceremony with the board and executive team. Trulieve reports operating 207 medical dispensaries, over 5,000 employees, and 3.5 million square feet of cultivation and production capacity across Florida, Georgia, Pennsylvania, and West Virginia, with $109 million in operating cash flow in the first half of 2026 and $325 million in cash at Q2-end.
Trulieve (NYSE: TRLV) completed its previously announced redomicile from British Columbia, Canada to Delaware, United States on August 11, 2026. The move was approved by shareholders on August 5, 2026, received a Final Order from the British Columbia Supreme Court on August 10, 2026, and became effective upon Delaware filings. Trulieve states the U.S. domicile may expand access to U.S. investors and enhance eligibility for broader index inclusion. The company’s subordinate voting shares continue trading on the New York Stock Exchange under ticker “TRLV”.
Trulieve (NYSE: TRLV) reported Q2 2026 revenue of $271 million, down 10% year-over-year and 6% sequentially, with 60% gross margin and GAAP gross profit of $162 million. Retail accounted for 94% of revenue. Adjusted net income was $20 million ($0.11 per diluted share) and adjusted EBITDA was $98 million, a 36% margin.
GAAP net loss attributable to common shareholders was $406 million ($2.10 per share), mainly reflecting a $403.3 million loss on the deconsolidation of Harvest. For the first half of 2026, cash flow from operations totaled $109 million and free cash flow $74 million, with quarter-end cash of $325 million.
The company listed on the New York Stock Exchange under the ticker TRLV, completed deconsolidation of Harvest’s mixed medical and adult-use operations, filed DEA applications for state-licensed medical operations after federal rescheduling to Schedule III, authorized a share repurchase program of up to the lesser of $50 million or 8,495,038 subordinate voting shares, began shipping to licensed independent pharmacies in Georgia, and opened five new Florida dispensaries. Trulieve now operates 207 dispensaries and 3.5 million square feet of cultivation and processing capacity in the U.S.
Trulieve (NYSE: TRLV) announced its planned participation in the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. Founder and CEO Kim Rivers is scheduled to join a fireside chat and hold investor meetings. Event information and materials are available on Trulieve’s investor events webpage.